BidaskClub cut shares of Express Scripts (NASDAQ:ESRX) from a strong-buy rating to a buy rating in a report issued on Friday morning.
A number of other brokerages also recently issued reports on ESRX. Mizuho set a $86.00 price target on shares of Express Scripts and gave the company a hold rating in a report on Wednesday, January 24th. SunTrust Banks reissued a buy rating and issued a $95.00 price objective on shares of Express Scripts in a report on Friday, January 12th. Royal Bank of Canada raised shares of Express Scripts from a sector perform rating to an outperform rating and set a $68.00 price objective on the stock in a report on Wednesday, January 31st. Sanford C. Bernstein downgraded shares of Express Scripts from a market perform rating to an underperform rating and raised their price objective for the stock from $55.80 to $77.50 in a report on Tuesday, January 30th. Finally, Robert W. Baird reissued a buy rating and issued a $92.00 price objective (up previously from $81.00) on shares of Express Scripts in a report on Tuesday, January 9th. Six analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of Hold and an average price target of $78.23.
Shares of Express Scripts (NASDAQ:ESRX) opened at $74.50 on Friday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.61 and a current ratio of 0.73. The stock has a market cap of $43,330.00, a PE ratio of 12.38, a PEG ratio of 0.85 and a beta of 0.93. Express Scripts has a 1-year low of $55.80 and a 1-year high of $83.49.
In other Express Scripts news, VP Glen D. Stettin sold 3,448 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $76.00, for a total transaction of $262,048.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Glen D. Stettin sold 3,449 shares of the firm’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $81.00, for a total transaction of $279,369.00. Following the sale, the vice president now owns 33,715 shares in the company, valued at approximately $2,730,915. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,001 shares of company stock worth $1,249,505. 0.68% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dodge & Cox raised its position in shares of Express Scripts by 25.7% during the second quarter. Dodge & Cox now owns 36,188,517 shares of the company’s stock valued at $2,310,275,000 after buying an additional 7,388,021 shares during the last quarter. Northern Trust Corp raised its position in shares of Express Scripts by 12.2% during the second quarter. Northern Trust Corp now owns 11,068,777 shares of the company’s stock valued at $706,629,000 after buying an additional 1,206,980 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Express Scripts by 23.5% during the third quarter. Ameriprise Financial Inc. now owns 5,233,327 shares of the company’s stock valued at $331,374,000 after buying an additional 996,816 shares during the last quarter. Macquarie Group Ltd. raised its position in shares of Express Scripts by 8.4% during the second quarter. Macquarie Group Ltd. now owns 11,880,919 shares of the company’s stock valued at $758,480,000 after buying an additional 922,406 shares during the last quarter. Finally, Pzena Investment Management LLC raised its position in shares of Express Scripts by 23.6% during the third quarter. Pzena Investment Management LLC now owns 3,509,800 shares of the company’s stock valued at $222,241,000 after buying an additional 670,922 shares during the last quarter. Institutional investors own 87.86% of the company’s stock.
About Express Scripts
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.